| Abstract [eng] |
Asthma is a common, chronic airway inflammatory disease affecting nearly 300 million people world-wide and found in 1-18% of the population in different countries. Bronchial asthma is known to be a heterogenous chronic respiratory disease. It is characterised by chronic inflammation of the bronchi, bronchoconstriction, increased bronchial reactivity or hyperresponsiveness and mucus hypersecretion. Severe eosinophilic allergic and non-allergic bronchial asthma presents a complex challenge for both patients and healthcare professionals. Finding the right treatment often involves navigating individual needs and variable responses. This study explores the potential of two promising biological therapies, benralizumab and omalizumab in specifically targeting this form of severe bronchial asthma. By exploring the therapeutic application, efficacy and clinical effectiveness of these agents, this research aims to empower healthcare professionals with valuable insights. This knowledge can translate into personalized and more effective treatment plans for patients struggling with severe eosinophilic bronchial asthma. To provide a comprehensive understanding, the research first delves into the underlying inflammatory mechanisms of this condition, drawing upon current research findings. It then explores the existing landscape of available biological therapies for this patient population, paving the way for a focused analysis of benralizumab and omalizumab. Finally, I was able to present two different case reports to substantiate my claim. I focused on two biological agents, benralizumab and omalizumab based on my case reports, and demonstrated their use and effectiveness in diverse patient contexts. By considering individual asthma endotypes, phenotypes, concomitant conditions, and clinical manifestations, I aimed to illustrate how these targeted therapies can be tailored to achieve optimal outcomes. In conclusion, these case studies provide a compelling demonstration of the effectiveness of biological therapies, particularly benralizumab and omalizumab, in the management of severe eosinophilic allergic bronchial asthma. Notable improvements in asthma control, lung function, and quality of life were evident in both patients. It is strongly recommended that patients with severe bronchial asthma seek consultation with both pulmonologists and allergists to determine the most appropriate biological agents based on individual asthma characteristics. Additionally ongoing research is crucial to explore and develop novel treatment approaches for this challenging condition. |
